Non-Small Cell Lung Cancer New Drug: Telisotuzumab vedotin for cMET Amplified NSCLC Ulas D. Bayraktar, MD 2025-06-09
Breast Cancer New Reference: Inavolisib with Palbociclib and Fulvestrant for Advanced ER+ Breast Cancer Ulas D. Bayraktar, MD 2025-06-02
Prostate Cancer New Reference: Enzalutamide with Radium-223 for Prostate Cancer Ulas D. Bayraktar, MD 2025-06-02
Bladder Cancer New Reference: Enfortumab Vedotin + Pembrolizumab for Advanced Urothelial Carcinoma Ulas D. Bayraktar, MD 2025-06-02
Colorectal Cancer New Reference: Encorafenib, Cetuximab with FOLFOX for bRAF Mutated Metastatic Colorectal Cancer Ulas D. Bayraktar, MD 2025-06-02
Multiple Myeloma New Indication: Daratumumab for High-Risk Smoldering Myeloma Ulas D. Bayraktar, MD 2025-06-02
Bladder Cancer New Protocol: Maintenance Sacituzumab Govitecan with Avelumab for Urothelial Carcinoma Ulas D. Bayraktar, MD 2025-06-02
Non-Small Cell Lung Cancer New Reference: Maintenance Atezolizumab for Stage IB-IIIA NSCLC Ulas D. Bayraktar, MD 2025-06-02
Chronic Lymphocytic Leukemia New Protocol: Zanubrutinib with Venetoclax for Untreated CLL Ulas D. Bayraktar, MD 2025-06-02
